Bristol-Myers Squibb Company (NYSE:BMY) Quarterly Analytical Analysis

The Firm owns an Arkansas state chartered subsidiary bank, Bank of the Ozarks. It has a 15.09 P/E ratio. The Firm provides permanent and contract staff to sectors, including information and communication technology (ICT), banking and finance, life sciences, engineering and energy.

Rainier Investment Management Llc decreased Bristol Myers Squibb Co (BMY) stake by 69.88% reported in 2016Q4 SEC filing. Oppenheimer & Co. Inc. boosted its stake in shares of Bristol-Myers Squibb by 40.5% in the third quarter. The United American Securities Inc holds 85,930 shares with $5.02 million value, down from 149,130 last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in shares of Bristol-Myers Squibb by 1.9% in the third quarter. The share price of the stock plunged -23.06% for the year. The hedge fund run by Joseph Edelman held 2.77 million shares of the health care company at the end of 2016Q4, valued at $75.98 million, up from 10,900 at the end of the previous reported quarter. New York-based Wellington Shields And has invested 1.45% in Bristol-Myers Squibb Co (NYSE:BMY). Year to date is 30.74%, 15.04% over the last quarter, 25.69% for the past six months and 39.21% over the last 12 months.

Since January 1, 0001, it had 0 insider buys, and 13 insider sales for $4.91 million activity. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) were released by: and their article: "Sarepta Therapeutics' (SRPT) CEO Ed Kaye On Q1 2017 Results - Earnings Call ..." published on April 28, 2017 as well as's news article titled: "Today's Research Reports on Trending Tickers: Sanofi and Sarepta Therapeutics" with publication date: May 01, 2017. AlphaOne also gave news stories about the biopharmaceutical company an impact score of 84 out of 100, meaning that recent news coverage is very likely to have an effect on the stock's share price in the next few days. New England & Retirement Grp owns 46,133 shares or 1.48% of their U.S. portfolio., Inc. (AMZN) climbed 0.91% and its total traded volume was 2.45 million shares contrast to the average volume of 3.25 million shares. Waterstone Capital Management L.P. owns 420,030 shares or 10.84% of their USA portfolio. Following the sale, the executive vice president now directly owns 488,063 shares of the company's stock, valued at $27,829,352.26. The Florida-based Glaxis Capital Management Llc has invested 4.24% in the stock. Oppenheimer & Co. Inc. now owns 363,030 shares of the biopharmaceutical company's stock worth $19,575,000 after buying an additional 104,669 shares during the period. About 90 shares traded. Wells Fargo & Co (NYSE:WFC) has risen 9.67% since May 26, 2016 and is uptrending. It has outperformed by 1.92% the S&P500. It also reduced Procter & Gamble Company (NYSE:PG) stake by 78,746 shares and now owns 2,651 shares. Johnson Ctls Intl Plc was raised too.

Since February 27, 2017, it had 1 insider buy, and 6 sales for $9.91 million activity. Investors may also be paying close concentration to some simple moving average indicators on shares of Bristol-Myers Squibb Company (BMY). LEUNG SANDRA had sold 92,405 shares worth $5.27 million. $681,240 worth of Bristol-Myers Squibb Co (NYSE:BMY) shares were bought by Samuels Theodore R. II. Investors of record on Friday, April 7th were issued a dividend of $0.39 per share. Its monthly volatility value of 0.88% and volatility for the week is valued at 1.17%. It dived, as 86 investors sold BMY shares while 529 reduced holdings. Kistler Tiffany Companies LLC raised its position in shares of Bristol-Myers Squibb by 11.3% in the first quarter. The stock witnessed -8% declines, -6.64% declines and 356.2% gains for the 1-month, 3-month and 6-month period, respectively. 7,330 were reported by Sfmg Limited Liability Co. Credit Suisse maintained Bristol-Myers Squibb Co (NYSE:BMY) rating on Monday, May 9. Moreover, Beech Hill Advsr has 0.33% invested in Bristol-Myers Squibb Co (NYSE:BMY). Gofen And Glossberg Ltd Liability Il invested 0.11% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Bristol Myers Squibbco now has $88.96 billion valuation. Private Advisor Ltd Liability holds 0.37% or 201,227 shares in its portfolio. Parsec Management holds 0.04% in Bristol-Myers Squibb Co (NYSE:BMY) or 6,972 shares. Rhenman & Prtnrs Asset Mngmt has 281,000 shares for 3.15% of their portfolio. Joel Isaacson And Ltd has invested 0.15% in Bristol-Myers Squibb Co (NYSE:BMY). Shufro Rose & Limited Company owns 461,480 shares for 3.01% of their portfolio. The stock is presently trading down its SMA-50 of $54.27. Finally, Morse Asset Management Inc purchased a new position in shares of Bristol-Myers Squibb during the first quarter valued at $609,000.

The consensus recommendation - averaging the work of 23 analysts - of 2.4 for Bristol-Myers Squibb Company (NYSE:BMY) points to moderate case. Therefore 41% are positive. SThree had 54 analyst reports since August 4, 2015 according to SRatingsIntel. Bristol-Myers Squibb has a consensus rating of "Hold" and a consensus price target of $62.57. Berenberg downgraded it to "Hold" rating and $70 target in Thursday, August 11 report. Jefferies Group LLC restated a "buy" rating and issued a $66.00 target price (up previously from $64.00) on shares of Bristol-Myers Squibb in a report on Saturday, March 11th. The company was maintained on Friday, April 29 by Barclays Capital. The rating was maintained by Jefferies with "Hold" on Tuesday, June 14. As per Monday, August 24, the company rating was upgraded by Piper Jaffray. The firm has "Buy" rating by UBS given on Friday, April 29. The rating was initiated by Hilliard Lyons with "Neutral" on Monday, May 23. Equities research analysts forecast that Bristol-Myers Squibb will post $2.95 EPS for the current year. During the same period in the previous year, the firm posted $0.74 earnings per share. BMY's profit will be $1.21B for 18.43 P/E if the $0.73 EPS becomes a reality. Its last 5-Year EPS growth stands at 4.20%; with earnings growth of 32.40% yoy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Latest News